Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July
April 17, 2014 at 10:23 AM EDT
Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, ...
